Innate Pharma (Nasdaq: IPHA) to meet investors at Jefferies Global Healthcare Conference 2026
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Innate Pharma S.A., a clinical-stage biotechnology company focused on cancer immunotherapies, filed a Form 6-K to share that its executive team will participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference 2026 in New York from June 2–4, 2026.
The company highlights its pipeline of potential first- or best-in-class antibody-based therapies, including IPH4502 for solid tumors, lacutamab for T-cell lymphomas, and monalizumab, which is being developed with AstraZeneca for non-small cell lung cancer. Innate also notes broader collaborations with partners such as Sanofi and AstraZeneca and its listings on Euronext Paris and Nasdaq.
Positive
- None.
Negative
- None.
Key Terms
clinical-stage biotechnology company, immunotherapies, Nectin-4 ADC, cutaneus T cell lymphomas, +1 more
5 terms
clinical-stage biotechnology company financial
"Innate Pharma SA ... a clinical-stage biotechnology company developing immunotherapies for cancer patients"
immunotherapies medical
"a clinical-stage biotechnology company developing immunotherapies for cancer patients"
Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.
Nectin-4 ADC medical
"IPH4502, a differentiated Nectin-4 ADC developed in solid tumors"
cutaneus T cell lymphomas medical
"lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas"
non-small cell lung cancer medical
"monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer"
A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.
FAQ
What did Innate Pharma (IPHA) announce in this Form 6-K?
Innate Pharma announced its executive team will participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference 2026 in New York, highlighting ongoing outreach to investors and interest in its cancer immunotherapy pipeline.
When and where will Innate Pharma attend the Jefferies Global Healthcare Conference 2026?
Innate Pharma will attend the Jefferies Global Healthcare Conference 2026 in New York, United States, from June 2 to June 4, 2026, with executives scheduled for one-on-one investor meetings during the event.
What kind of company is Innate Pharma (IPHA) according to the filing?
Innate Pharma is described as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients, leveraging antibody-engineering expertise and innovative target identification to create next-generation antibody therapeutics with a focus on areas of high unmet medical need.
Which key drug candidates does Innate Pharma highlight in this report?
Innate Pharma highlights IPH4502, a differentiated Nectin-4 ADC for solid tumors, lacutamab, an anti-KIR3DL2 antibody for T-cell lymphomas, and monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer, as core assets in its oncology pipeline.
What major collaborations does Innate Pharma mention in the 6-K content?
Innate Pharma notes collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as partnerships with academic and research institutions, to advance innovation in immuno-oncology and support the development of its antibody-based cancer therapies.